Tag Archive for: AMR

Destiny Pharma Lancet Report

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Destiny Pharma’s Call to Arms to Combat AMR

CEO Neil Clark and CSO Dr Bill Love from Europe’s leading anti-infectives biotech company Destiny Pharma, on how the makers and influencers of health policy could fuel a renaissance in drug development…